Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF
Back

A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF

Stopped

Open to: ALL

Age: 40.0 - 89.0

Nottingham Southampton Edinburgh London Cambridge Manchester Liverpool Leicester Cottingham

Medical Conditions

Cough
Chronic Cough

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Idiopathic pulmonary fibrosis (IPF) is a rare, progressive life-threatening disease that is characterized by exertional dyspnea and persistent dry cough.

Cough in IPF is both a presenting and a complicating clinical feature, which affects approximately three quarters of IPF cases. It is often a debilitating symptom that adversely affects quality of life (QoL) and is usually refractory to medical therapy.

Inhaled RVT-1601 (formerly, PA101B), a new inhalation formulation of cromolyn sodium delivered via the eFlow® Closed System (CS) nebulizer, is being evaluated in this Phase 2b study for the treatment of persistent cough in patients with IPF.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2019 May 2020

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Inhaled RVT-1601 administered TID via eFlow nebulizer

Intervention Arm Group : RVT-1601 High Dose;RVT-1601 Low Dose;RVT-1601 Mid Dose;

Intervention Type : DRUG
Intervention Description : Inhaled Placebo administered TID via eFlow nebulizer

Intervention Arm Group : Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Nottingham University Hospital
    Nottingham
  • University Hospital Southampton
    Southampton
  • University of Edinburgh
    Edinburgh
  • Royal Brompton Hospital
    London
  • Royal Papworth Hospital
    Cambridge
  • University of Manchester
    Manchester
  • University Hospital Aintree
    Liverpool
  • University of Leicester
    Leicester
  • Castle Hill Hospital
    Cottingham
    East Yorkshire


The study is sponsored by Respivant Sciences GmbH and is in collaboration with Respivant Sciences Inc..



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT03864328
Last updated 08 June 2020

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top